HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rapid Release, Rapid Success: Tylenol Launch Spawns Generic Imitators

This article was originally published in The Tan Sheet

Executive Summary

The recent success of Tylenol Extra Strength Rapid Release Gels has caught the attention of private labelers

You may also be interested in...



Acquisition Primes Airborne For Claims Overhaul

GF Capital Private Equity Fund is overhauling Airborne Inc. to steer the firm clear of the regulatory issues that have plagued it

New Products In Brief

Motrin IB Liquid Caps: McNeil Consumer & Specialty Pharmaceuticals introduces Motrin IB Liquid Caps 200 mg "for people who don't fool around with pain." Expected in stores this fall, the SKU "contains the #1 Doctor recommended OTC medicine for back pain," package labeling states. Liquid Caps are available in a 20-count package starting at $3.75, a 40-count pack for $6.30 and an 80-count pack for $8.99. The launch is likely being fueled by the success of other liquid capsule formulations such as Tylenol Rapid Release Gels and Advil Liqui-Gels. Leiner Health Products announced in June it would launch a store brand equivalent to Tylenol Rapid Release in light of strong sales in the liqui-gel category (1"The Tan Sheet" June 13, 2005, p. 5). McNeil also is extending its Liquid Cool Burst line with Sore Throat daytime and nighttime. The 8 oz. bottle will start at $6.39 and contain 1,000 mg acetaminophen per serving...

Advil Liqui-Gel Sales Increase Despite NSAID Troubles

Second quarter sales of Wyeth's Advil Liqui-Gels increased 25% to $21.9 mil., even though the overall NSAID category decline led to weaker domestic sales of Advil-brand products

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel